Approval of Akugo Drug Price by Central Social Insurance Medical Council | May 13, 2026

Performance Overview

Samba Bio's drug price for Akugo has been approved by the Central Social Insurance Medical Council, and the final drug price is expected to be set at 72,716,528 yen. Accordingly, the consolidated earnings forecast for the January 2027 period has been revised to project business revenue of 396 million yen, operating income of -5,229 million yen, and net income attributable to owners of parent of -5,133 million yen. The company plans to progress through clinical trials and medical collaborations in stages, and expectations for future developments are rising.

Outlook and Impact on Shareholders

With the approval of the Akugo drug price, efforts will be made to advance clinical trials and the adoption in medical institutions, aiming for phased revenue generation. Although the earnings forecast for the January 2027 period remains cautious, further improvements are anticipated depending on the progress of drug price decisions and clinical development. The company will continue to focus on strengthening clinical trials and healthcare infrastructure to enhance long-term corporate value.